Prot #UCART123_01: Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered

Project: Research project

Project Details

StatusActive
Effective start/end date11/10/2011/10/23

Funding

  • Cellectis S.A. (Prot #UCART123_01)